Comparative Pharmacology
Head-to-head clinical analysis: PERMAPEN versus PFIZERPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERMAPEN versus PFIZERPEN.
PERMAPEN vs PFIZERPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Permapen (penicillin G benzathine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing autolysin activation, leading to cell lysis.
250 mg intramuscularly every 4 weeks as a single injection.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-5 hours in end-stage renal disease
Terminal elimination half-life: ~0.5-1 hour (adults with normal renal function); prolongs to 7-10 hours in end-stage renal disease. Clinical context: short half-life requires frequent dosing (q4-6h) or continuous infusion for severe infections.
Renal: 60-70% as unchanged drug; hepatic metabolism: ~30% to penicilloic acid; fecal: <10%
Primarily renal tubular secretion (60-90% unchanged) and glomerular filtration; about 10% biliary/fecal. In neonates, renal clearance is reduced.
Category C
Category C
Penicillin antibiotic
Penicillin antibiotic